Who are Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): M-VTD-PACE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dexamethasone-rituximab-cyclophosphamide-bortezomib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib (Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy and immunotherapy regimen. Area: Oncology.

phase 3 Combination chemotherapy and immunotherapy regimen CD20 (rituximab), proteasome (bortezomib), DNA alkylation (cyclophosphamide), glucocorticoid receptor (dexamethasone) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib (Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib) — University of Ulm. This combination regimen uses a corticosteroid, B-cell depleting antibody, alkylating agent, and proteasome inhibitor to suppress immune cells and induce apoptosis in malignant plasma cells.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib TARGET	Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib	University of Ulm	phase 3	Combination chemotherapy and immunotherapy regimen	CD20 (rituximab), proteasome (bortezomib), DNA alkylation (cyclophosphamide), glucocorticoid receptor (dexamethasone)
M-VTD-PACE	M-VTD-PACE	University of Arkansas	phase 3	Combination chemotherapy and immunotherapy regimen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy and immunotherapy regimen class)

University of Arkansas · 1 drug in this class
University of Ulm · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib — Competitive Intelligence Brief. https://druglandscape.com/ci/dexamethasone-rituximab-cyclophosphamide-bortezomib. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab